Lajos Pusztai

发表

The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data

Kevin R. Coombes, Jing Wang, Sijin Wen, 2009, Cancer informatics.

An adaptive feature selection method for microarray data analysis

Leming Shi, Jie Cheng, Shu Zheng, 2012, 2012 IEEE International Conference on Bioinformatics and Biomedicine.

Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses

René Natowicz, Euler Guimarães Horta, Roman Rouzier, 2008, BMC Bioinformatics.

Computing Molecular Signatures as Optima of a Bi-Objective Function: Method and Application to Prediction in Oncogenomics

Patrick Siarry, René Natowicz, Rachid Chelouah, 2015, Cancer informatics.

TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.

Weiwei Shi, Christos Hatzis, Lajos Pusztai, 2018, JCO clinical cancer informatics.

Uncertainty estimation with a finite dataset in the assessment of classification models

Rong Tang, Weijie Chen, Brandon D. Gallas, 2012, Comput. Stat. Data Anal..

Building networks with microarray data.

Kim-Anh Do, Lajos Pusztai, Waree Rinsurongkawong, 2010, Methods in molecular biology.

Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems

Yuan Qi, W. Fraser Symmans, Lajos Pusztai, 2011, BMC Bioinformatics.

S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome.

Lajos Pusztai, Catherine M. Kelly, Takayuki Iwamoto, 2011 .

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Zhi Hu, Wen-Lin Kuo, Gordon B Mills, 2008, Cancer research.

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer

Lajos Pusztai, Achim Rody, Marcus Schmidt, 2014, Genomics data.

Effect of training-sample size and classification difficulty on the accuracy of genomic predictors

Leming Shi, Weiwei Shi, Mauro Delorenzi, 2010, Breast Cancer Research.

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

David Wholley, Anne Wallace, Michael Hogarth, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer biomarkers and molecular medicine

Lajos Pusztai, Mark Ayers, J. Stec, 2003, Expert review of molecular diagnostics.

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?

Lajos Pusztai, Takayuki Iwamoto, L. Pusztai, 2010, Genome Medicine.

Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response

Roman Rouzier, Lajos Pusztai, Terry L. Smith, 2004, Cancer.

The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer

Nikhil G Thaker, Lajos Pusztai, Karen E Hoffman, 2015, SpringerPlus.

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations

Lajos Pusztai, Diether Lambrechts, Christine Desmedt, 2017, Nature Communications.

Evaluation of biological pathways involved in chemotherapy response in breast cancer

Jing Wang, Lajos Pusztai, Christos Sotiriou, 2008, Breast Cancer Research.

Reproducibility of research and preclinical validation: problems and solutions

Christos Hatzis, Lajos Pusztai, Fabrice Andre, 2013, Nature Reviews Clinical Oncology.

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity

Tingting Jiang, Weiwei Shi, Jorge S. Reis-Filho, 2018, bioRxiv.

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer

Christos Hatzis, Lajos Pusztai, Kurt A. Schalper, 2016, Breast Cancer Research.

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.

Benjamin Haibe-Kains, Zoltan Szallasi, Charles Swanton, 2010, The Lancet. Oncology.

Commercialized multigene predictors of clinical outcome for breast cancer.

Christos Hatzis, Lajos Pusztai, G. Hortobagyi, 2008, The oncologist.

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

Philippe Dessen, Stefan Michiels, Lajos Pusztai, 2009, Clinical Cancer Research.

Improving patient care through molecular diagnostics.

Lajos Pusztai, Edith A Perez, M. J. van de Vijver, 2004, Seminars in oncology.

Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes

Funda Meric-Bernstam, Kim-Anh Do, Gordon B Mills, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Christos Hatzis, Lajos Pusztai, Henry Kuerer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.

Lajos Pusztai, Fabrice Andre, G. Hortobagyi, 2006, Biochimica et biophysica acta.

Targeted therapies for cancer 2004.

Geoffrey S Ginsburg, Lajos Pusztai, G. Ginsburg, 2004, American journal of clinical pathology.

Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer.

Roman Rouzier, Lajos Pusztai, Florence Huguet, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Lajos Pusztai, Christos Sotiriou, Kenneth R Hess, 2007, The Lancet. Oncology.

Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments

Yuan Qi, Weiwei Shi, W. Fraser Symmans, 2015, PloS one.

Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry

Kelly K. Hunt, Kevin R. Coombes, Lajos Pusztai, 2004, Breast Cancer Research and Treatment.

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients

Christos Hatzis, Lajos Pusztai, Balázs Győrffy, 2015, Genome Medicine.

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

Vamsidhar Velcheti, David L Rimm, Lajos Pusztai, 2014, Clinical Cancer Research.

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

Yuan Qi, Lajos Pusztai, Charles Coutant, 2010, Cancer research.

Chips to Bedside: Incorporation of Microarray Data into Clinical Practice

Lajos Pusztai, L. Pusztai, 2006, Clinical Cancer Research.

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

Yuan Qi, Lajos Pusztai, Charles Coutant, 2011, Journal of the National Cancer Institute.

Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated

Funda Meric-Bernstam, Rinath Jeselsohn, Lajos Pusztai, 2014 .

Intratumor Heterogeneity: Seeing the Wood for the Trees

Charles Swanton, Lajos Pusztai, P. A. Futreal, 2012, Science Translational Medicine.

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

Roman Rouzier, Lajos Pusztai, Kenneth R Hess, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cell proliferation in cancer : regulatory mechanisms of neoplastic cell growth

Lajos Pusztai, Claire E. Lewis, L. Pusztai, 1996 .

Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes

W. Fraser Symmans, Lajos Pusztai, G. Hortobagyi, 2007, Clinical Cancer Research.

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Lajos Pusztai, Rita Nanda, L. Pusztai, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic index of sensitivity to endocrine therapy for breast cancer.

Peter Regitnig, Christos Hatzis, Lajos Pusztai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer

Yuan Qi, Lajos Pusztai, William F Symmans, 2011, Breast Cancer Research.

Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

Roman Rouzier, Lajos Pusztai, G. Hortobagyi, 2005, Cancer.

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Christos Hatzis, Lajos Pusztai, Bilge Aktas, 2017, Cancer research.

Molecular classification of breast cancer: limitations and potential.

Lajos Pusztai, L. Pusztai, K. Anderson, 2006, The oncologist.

High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients

Funda Meric-Bernstam, Kim-Anh Do, Lajos Pusztai, 2012, Breast Cancer Research and Treatment.

Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients

Roberto Tagliaferri, Francesco Iorio, Antonio Eleuteri, 2011, Breast Cancer Research and Treatment.

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

Yuan Qi, W. Fraser Symmans, Lajos Pusztai, 2012, Breast Cancer Research and Treatment.

Maximizing biomarker discovery by minimizing gene signatures

Weida Tong, Jennifer Fostel, Youping Deng, 2011, BMC Genomics.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Yuan Qi, Christos Hatzis, Lajos Pusztai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier, Charles M. Perou, W. Fraser Symmans, 2005, Clinical Cancer Research.

RefSeq Refinements of UniGene-Based Gene Matching Improve the Correlation of Expression Measurements Between Two Microarray Platforms

Kevin Coombes, Sijin Wen, W. Fraser Symmans, 2006, Applied bioinformatics.

Current status of prognostic profiling in breast cancer.

Lajos Pusztai, L. Pusztai, 2008, The oncologist.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Roman Rouzier, Lajos Pusztai, J. Ross, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer

Roman Rouzier, Lajos Pusztai, Donald Berry, 2006, Cancer.

Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma

Lajos Pusztai, Terry L. Smith, G. Hortobagyi, 2004, Cancer.

Reproducibility of Gene Expression Signature–Based Predictions in Replicate Experiments

Lajos Pusztai, Kenneth R Hess, Mini Kapoor, 2006, Clinical Cancer Research.

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Roman Rouzier, Lajos Pusztai, Kenneth R Hess, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Targeted Therapy in Breast Cancer

Lajos Pusztai, K. Bloom, J. Stec, 2004, Molecular & Cellular Proteomics.

Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer

Lajos Pusztai, Kenneth R Hess, K. Hess, 2007, Clinical Cancer Research.

A clinically relevant gene signature in triple negative and basal-like breast cancer

Lajos Pusztai, Achim Rody, Marcus Schmidt, 2010, Breast Cancer Research.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Anne M Wallace, Michael Hogarth, Lajos Pusztai, 2016, The New England journal of medicine.

Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers

Tingting Jiang, Christos Hatzis, Lajos Pusztai, 2014, Breast Cancer Research and Treatment.

On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.

Lajos Pusztai, Christos Sotiriou, Stephen B. Fox, 2019, Journal of Clinical Oncology.

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

Funda Meric-Bernstam, Lajos Pusztai, Diane D. Liu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical application of cDNA microarrays in oncology.

Lajos Pusztai, Mark Ayers, J. Stec, 2003, The oncologist.

Breast cancer biomarkers and molecular medicine: part II

Lajos Pusztai, Mark Ayers, J. Stec, 2004, Expert review of molecular diagnostics.

Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer

Lajos Pusztai, L. Pusztai, L. Gianni, 2004, Nature Clinical Practice Oncology.

Gene-expression signatures in breast cancer.

Lajos Pusztai, Christos Sotiriou, C. Sotiriou, 2009, The New England journal of medicine.

Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures

Lajos Pusztai, Eugen Ruckhäberle, Achim Rody, 2011, PloS one.

A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer.

Lajos Pusztai, Fangyong Li, L. Pusztai, 2015, The New England journal of medicine.

Gene expression profiling of breast cancer

Lajos Pusztai, L. Pusztai, 2009, Breast Cancer Research.

Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?

Roman Rouzier, Lajos Pusztai, L. Pusztai, 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.

Lajos Pusztai, Fabrice André, Takayuki Iwamoto, 2013, The oncologist.

Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

Yuan Qi, W. Fraser Symmans, Lajos Pusztai, 2010, Clinical Cancer Research.

The bimodality index

Kevin R. Coombes, Jing Wang, Sijin Wen, 2009 .

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Yuan Qi, Jie Zhang, Christos Hatzis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Michael Hogarth, Lajos Pusztai, Rita Nanda, 2016, The New England journal of medicine.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

Paul Ellis, Terence P. Speed, Benjamin Haibe-Kains, 2010, Proceedings of the National Academy of Sciences.

Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

Lajos Pusztai, Francisco J Esteva, 2005, Oncology.

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

Oriana Ciani, Carla Rognoni, Lajos Pusztai, 2015, Breast Cancer Research and Treatment.

Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial

Yuan Qi, Nan Song, Kui Shen, 2012, BMC Medical Genomics.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Kevin R Coombes, Lajos Pusztai, Eugen Ruckhäberle, 2012, European journal of cancer.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Mei Liu, Wei, Christos Hatzis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multifactorial approach to predicting resistance to anthracyclines.

Yuan Qi, Gianluca Bontempi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.